Homozygous Mutations in PXDN Cause Congenital Cataract, Corneal Opacity, and Developmental Glaucoma  by Khan, Kamron et al.
REPORT
Homozygous Mutations in PXDN
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Anterior segment dysgenesis describes a group of heterogeneous developmental disorders that affect the anterior chamber of the eye and
are associated with an increased risk of glaucoma. Here, we report homozygous mutations in peroxidasin (PXDN) in two consanguineous
Pakistani families with congenital cataract-microcornea with mild to moderate corneal opacity and in a consanguineous Cambodian
family with developmental glaucoma and severe corneal opacification. These results highlight the diverse ocular phenotypes caused
by PXDNmutations, which are likely due to differences in genetic background and environmental factors. Peroxidasin is an extracellular
matrix-associated protein with peroxidase catalytic activity, and we confirmed localization of the protein to the cornea and lens epithe-
lial layers. Our findings imply that peroxidasin is essential for normal development of the anterior chamber of the eye, where it may have
a structural role in supporting cornea and lens architecture as well as an enzymatic role as an antioxidant enzyme in protecting the lens,
trabecular meshwork, and cornea against oxidative damage.Anterior segment dysgenesis (ASD) describes a group of
ocular developmental disorders affecting the anterior
chamber structures behind the cornea and in front of the
lens, including the iris, trabecular meshwork, and ciliary
body.1,2 These abnormalities can give rise to elevated intra-
ocular pressure through obstruction of the trabecular
meshwork drainage channels, increasing the risk of devel-
oping glaucoma.3 Examples of this phenotype include
Axenfeld-Rieger syndrome due to dominant mutations
in FOXC1 (MIM 601090)4,5 or PITX2 (MIM 601542),6,7
isolated aniridia caused by dominant mutations in PAX6
(MIM 607108),8,9 isolated trabeculodysgenesis resulting
from recessive mutations in CYP1B1 (MIM 601771),10
and megalocornea associated with microspherophakia
caused by recessive mutations in LTBP2 (MIM
602091).11,12 Some anterior segment anomalies are also
associated with cataracts, because during development
the anterior lens secretes factors that induce the differ-
entiation of the cornea and trabecular meshwork.13,14
Examples of corneal opacity or microcornea with cataract
include dominant mutations in CRYAA (MIM 123580),15
CRYBA4 (MIM 123631),16 CRYBB1 (MIM 600929),17
CRYBB2 (MIM 123620),18 CRYGC (MIM 123680),19
CRYGD (MIM 123690),15 GJA8 (MIM 600897),15,20–22
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may be expressed asymmetrically and can be highly vari-
able, even between affected family members, because of
genetic background and environmental factors.
We recently described genetic heterogeneity for reces-
sively inherited congenital cataract-microcornea with
corneal opacity (CCMCO) in three unrelated consanguin-
eous families, MEP57, MEP60 and MEP68, from the Pun-
jab province of Pakistan.30 We have since ascertained
one additional Pakistani family, MEP59, with a history of
poor vision that fits the description for CCMCO (Figure 1
and Table 1). Microcornea and corneal opacification, due
to the sclera encroaching on the cornea, were the defining
features for these families, with variable degrees of ex-
pression between affected members of the same family.
Concurrently, through an epidemiological survey of blind
schools in Cambodia,31 we also identified a consanguin-
eous family, CA2, in which four affected individuals
had severe developmental glaucoma associated with
extensive corneal opacification and buphthalmos (Figure 2
and Table 1). In all the families described in this study,
the patients did not have any systemic problems, or any
neurological abnormalities, and the unaffected family
members did not show any eye defects. The purpose
of the current study was to identify the pathogenicSt James University Hospital, Leeds LS9 7TF, UK; 3Department of Ophthal-
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Figure 1. Clinical Features of the CCMCO Patients
(A and B) Pedigrees for MEP60 (A) and MEP59 (B). Individuals from whom DNA is available are numbered. Photos of the anterior
segment of affected family members 2316 (V.1, aged 16 years) and 2318 (V.7, aged 8 years) from MEP60 as well as family members
2314 (IV.4, aged 18 years) and 2310 (IV.3, aged 14 years) fromMEP59 are also shown. The left eye of 2310 (IV.3) is aphakic, and capsular
condensation, the white ring that is visible, is present. Note variable central or peripheral corneal opacifications present in all cases,
thoughmost eyes have a well-defined corneoscleral junction. Strabismus in the amblyopic eye is also apparent. The clinical descriptions
are presented in Table 1.mutations responsible for anterior segment dysgenesis in
these families.
This study was performed via a process approved by the
Pakistan Medical Foundation, Lahore; the Leeds (East)
Research Ethics Committee; the Royal Adelaide Hospital
Research Ethics Committee; the Southern Adelaide Clin-
ical Human Research Ethics Committee; and the National
Ethics Committee for Human Research, Cambodia. Partic-
ipants gave informed consent in accordance with the
tenets of the Declaration of Helsinki. In all families studied
herein the ocular abnormalities either were severe enough
to be noted at birth or became apparent within the first
year of life and did not progress thereafter. In the Pakistani
cases, the anterior chambers were of near-normal depth
with no obvious anterior capsular abnormality, though
where clinically visible, the lenses were cataractous but
with normal contour and size. Affected individuals had
a normal fundus appearance observed through examina-
tion with an indirect ophthalmoscope. Peripheral blood
was obtained and genomic DNA extracted according to
standard procedures. In the Cambodian family, three
patients (C, H, and K [IV.3, IV.8, and IV.11 in Figure 2])
displayed bilateral buphthalmos and severe opacification
and vascularization of the cornea, with the fourth affected
individual (J [IV.10 in Figure 2]) displaying severe corneal
opacification. In three patients (C, J, and K [IV.3, IV.10,
and IV.11 in Figure 2]), intraocular pressure, measured by
iCare tonometry, was markedly elevated. The extent ofThe Americancorneal opacification prevented visualization of the ante-
rior chamber or fundus and whether cataracts were present
in all affected patients. Saliva samples were collected in
OrageneDNA Collection Kits (DNA Genotek) for extrac-
tion according the manufacturer’s protocol.
Homozygosity mapping and linkage analysis in Pakis-
tani family MEP60 implicated two shared homozygous
regions in all the affected members.30 The pathogenic
mutation mapped within either a 6.7 Mb (14.1 cM)
interval extending from 2pter to microsatellite marker
D2S281, which contained 20 genes, or a 3.8 Mb (7.5 cM)
region on chromosome 20 spanning D20S906 (1.5 Mb)
to D20S835 (5.3 Mb) and containing 55 genes.30 Given
the lack of any obvious candidate genes, we prepared
a customized liquid-phase SureSelect Target Enrichment
biotinylated cRNA bait, using the Agilent Technologies
eArray platform. This reagent was designed against all
coding exons and 20 bp regions flanking the exons from
Refseq genes within the critical intervals on chromosomes
2 and 20. After merging of overlapping exons, 810 of
814 regions amounting to 135 kb DNA nucleotide
sequence were covered, with only 120 bp missing due to
homology with repetitive sequences. We then sheared
3 mg DNA from patient 2316 (V.1 in Figure 1A) by sonica-
tion, before ligation onto Illumina paired-end adapters
according to standard procedures. This mixture was
hybridized against the customized baits and eluted to
capture the enriched DNA library, which was sequencedJournal of Human Genetics 89, 464–473, September 9, 2011 465
Table 1. Clinical Features of Patients with Homozygous PXDN Mutations
MEP60 MEP59 CA2
2316
(V.1)
2318
(V.7)
2319
(V.2)
2310
(IV.3)
2311
(IV.1)
2313
(IV.2)
2314
(IV.4)
C
(IV.3)
H
(IV.8)
J
(IV.10)
K
(IV.11)
Cornea
Corneal diameter
OD;OS (mm)
7; 7 7; 8 smalla 5; 9 smalla smalla 8; 8 largea largea smalla largea
Vascularisation        þþ þþ þþ þþ
Opacity p>c p>c p>c p; OD>OS p p p þþ þþ þþ þþ
Central corneal
thickness OD;OS (mm)
ND ND ND ND ND ND ND 175;455 a;a a;828 332;277
Globe
Microphthalmia    ? ? ? ?    
Buphthalmos        þ þ  þ
Intraocular pressure
OD;OS (mm Hg)
ND ND ND ND ND ND ND 45;37 19;8 30;19 25;10
Iris
Irido-corneal
adhesion
p p p     no view no view no view no view
Iris Coloboma        no view no view no view no view
Irido-lenticular
adhesions
       no view no view no view no view
Iris hypoplasia        no view no view no view no view
Lens
Kerato-lenticular
touch
       no view no view no view no view
Cataract þ þ þ þ þ þ þ no view no view no view no view
Function
Nystagmus        ? ? ? ?
Vision CF CF CF CFb 6/60 6/60 6/19b NPL/NPL PL/NPL NPL/PL PL/PL
All patients in families MEP60 and MEP59 had a normal fundal exam; no view of the fundus could be obtained of any affected members of CA2. The meanings of
the symbols used in the table are as follows;þ, present;þþ, present in a severe form;, absent; p, peripheral; c, central; OD, right eye; OS, left eye; ND, not done;
CF, counting fingers; NPL, no perception of light; PL, perception of light.
a Exact measurement unavailable.
b With aphakic correction.for 80 bp single-end reads on the Illumina Genome
Analyzer GAIIx (Illumina).
The raw data files were processed by the Illumina pipe-
line (version 1.3.4) and the sequencing reads were aligned
to the human reference sequence (hg19/GRCh37) with
Novoalign software (Novocraft Technologies). Alignments
were processed in the SAM/BAM format32 with Picard and
the Genome Analysis Toolkit (GATK)33 Java programs in
order to correct alignments around indel sites and mark
potential PCR duplicates. The mean depth of coverage
for the targeted region was 242 reads; however, after dupli-
cate removal the mean depth amounted to 79 reads, with
minimum mapping and base phred quality scores of 20
and 17, respectively. Of the targeted bases, 92% were
covered by at least five reads matching these criteria. Vari-
ants for the coding regions and the 20 bp flanking regions466 The American Journal of Human Genetics 89, 464–473, Septembwere reported in the VCF format through the use of the
Unified Genotyper and DINDEL34 functions of GATK
before filtering against variants recorded in dbSNP131. A
total of 125 variants were detected, 118 of which were
identified in dbSNP131. This left two intronic (not splice
site) variants, four nonsynonymous variants, and a dele-
tion, of which only two were unique to MEP60 and absent
from seven unrelated DNA samples that were run in
a parallel experiment (Table S1 available online); a homozy-
gous G-to-C nucleotide change in the coding sequence of
TGM6 (transglutaminase 6 [MIM 613900], NM_198994.2)
(on chromosome 20) that substitutes a serine for an argi-
nine residue (c.1995G>C [p.Arg665Ser]) and a homozy-
gous deletion of a C nucleotide in the coding sequence
of PXDN (peroxidasin [MIM 605158], NM_012293.1) (on
chromosome 2) that creates a frameshift and prematureer 9, 2011
Figure 2. Clinical Features in Buphthalmic Patients
Pedigree for CA2. Individuals from whom DNA is available are de-
picted by a letter. Photos of the anterior segment of affected family
members C (IV.3, aged 25 years), H (IV.8, aged 15 years), J (IV.10,
aged 10 years), and K (IV.11, aged 8 years) are shown. Note that
gross buphthalmos prevented accurate measurement of corneal
diameter and that severe corneal opacification prevented both
visualization of the anterior chamber or acquisition of accurate
biometric data, with the exception of corneal thickness. The
clinical descriptions are presented in Table 1.truncation of the protein (c.2568delC [p.Cys857AlafsX5]).
The functional impact of the TGM6 variant was assessed
with the PolyPhen algorithm. With the use of a HumVar
model, a score of 0.021 predicted that the TGM6 variant
was benign. It was therefore considered likely that the
truncating PXDN mutation was pathogenic. Presence of
this mutation and segregation with CCMCO in family
MEP60 (Figure 1A) was confirmed by direct sequencingThe Americanof exon 17 of PXDN with oligonucleotide primer 17BF
on an ABI3130xl Genetic Analyzer (Figure 3A), and this
change was excluded from 170 ethnically matched control
DNA samples (340 chromosomes). Primer pairs used in the
PCR amplification and sequencing are depicted in Table S2.
Genetic analysis in two other Pakistani families who fit
the diagnostic criteria for CCMCO, MEP57 and MEP68,
failed to identify linkage to the 2pter interval harboring
PXDN.30 However, another such family,MEP59, was linked
to this region (Figure S1). Direct sequencing of PXDN in
affected member 2311 (IV.1 in Figure 1B) identified a
missense change in exon 17 that changed an arginine
residue to a cysteine (c.2638C>T [p.Arg880Cys]) (Fig-
ure 3B). This variant scored 0.979 with PolyPhen under
the HumVar model, suggesting that it is likely to be func-
tionally damaging. Furthermore, the mutation changes
a conserved arginine residue within the peroxidase domain
and is likely to affect the three-dimensional structure of
the protein because the new cysteine is within the atomic
range for interacting with one of the cysteines in the native
disulfide bond (Figure 4). This mutation was predicted to
disrupt the enzymatic catalytic site and is therefore likely
to be pathogenic. Themutation segregatedwith the disease
in MEP59 (Figure 1B) as expected for recessive inheritance,
following direct sequencing of exon 17 with oligonucleo-
tide primer 17BF, and was absent from 340 ethnically
matched chromosomes.
Independently of the above analysis, homozygosity
mapping in the consanguineous Cambodian family CA2
also revealed linkage to 2pter (Figure S2). Each of the four
affected siblings had a single region in common between
the telomere and rs1821797 (5.7 Mb; 13.0 cM). Primers
were designed for 218 amplicons covering the annotated
exons and splice-site flanking regions within the linked
interval (NCBI 36 and ENSEMBL release 54). PCR products
from the proband were sequenced on an ABI3730xl DNA
Analyzer according to standard protocols. The data were
analyzed with Sequencher V4.09 (GeneCodes) by com-
parison with the reference sequence (NCBI/GenBank). In
total, 110 variants were identified, 103 of which were re-
corded in dbSNP131. Of the seven variants remaining,
only one mapped within an exon. This variant, in exon
10 of PXDN, was predicted to cause premature protein
truncation and so is likely to be the pathogenic mutation
in CA2 (c.1021C>T [p.Arg341X]) (Figure 3C). The muta-
tion segregated with disease in family CA2 (Figure 2)
following direct sequencing of exon 10 with oligonucleo-
tide primer 10R and was absent from 58 ethnically
matched control chromosomes.
The 23 exon human PXDN, also known as MG50 (mela-
noma-associated gene 50),35,36 KIAA0230,37 PRG2 (p53-
responsive gene 2 protein)38 and VPO1 (vascular peroxi-
dase 1),39 encodes a 1479 amino acid protein with a unique
structure containing a mammalian peroxidase domain
and motifs that are typically found in extracellular matrix
proteins (Figure 4A). The peroxidase domain consists of
a heme-binding cavity, critical catalytic residues, and aJournal of Human Genetics 89, 464–473, September 9, 2011 467
Figure 3. Genetic Analysis of CCMCO and
Buphthalmic Patients
(A–C) Sequence chromatograms highlighting
the PXDN mutation in affected patients from
MEP60 (A), MEP59 (B), and CA2 (C) are shown
against the wild-type sequence from a healthy
individual.calcium binding site, similar to the known mammalian
peroxidases myeloperoxidase (MPO), lactoperoxidase
(LPO), eosinophil (EPX), and thyroid peroxidases
(TPO).39 MPO, LPO, and EPX have a role in antimicrobial
defense by oxidation of microbial proteins targetingFigure 4. Molecular Analysis of PXDN
(A) Diagrammatic representation of PXDN. The protein sequence (NP_036425.1) was a
the domains in the protein, the disulfide bridges, and the active site histidine residues a
to the full-length 1479 amino acid protein are also highlighted.
(B, C, D, and E). Analysis of the PXDN missense mutation in MEP59. (B) Protein seq
mammalian vertebrates using the Vertebrate Multiz Alignment and PhastCons Cons
The diagram shows the conserved arginine (R) residue in the normal sequence that is
(C) Ribbon representation of the peroxidase domain in PXDN. The structural model w
server.58,59 The bovine peroxidase (PDB 3q9k) and humanmyeloperoxidase (PDB 1d2
peroxidase domain sequence shared more than 40% sequence identity, with over 90
The quality and stereochemistry of the model was assessed with ProSA-II and PROCHE
The heme group is depicted in blue, and active site histidines (H824 andH1074) are in
also shown. R880 (D) and C880 (E) are shown as stick representations and colored by
away from C857, which is within atomic range for disulfide bond formation.
468 The American Journal of Human Genetics 89, 464–473, September 9, 2011them for degradation, and TPO is involved
in catalyzing the iodination of thyroid
hormones. The main catalytic function of
mammalian peroxidasin is the metabolismof hydrogen peroxide, although the in vivo substrate for
this reaction is currently unknown.39,40 The other motifs
in peroxidasin consist of an amino-terminal secretory
signal sequence, domains that are involved in ligand
binding, including five leucine-rich repeat regions,41 fournalyzedwith the SMART program. The position of
re shown. The positions of the mutations relative
uence conservation across mammalian and non-
ervation package at the UCSC Genome Browser.
mutated to a cysteine in patients with CCMCO.
as derived by homology modeling using the M4T
v) were used as templates. Both templates and the
% coverage, thus ensuring structural similarity.60
CK, and the figures were generated using PyMOL.
red. The disulfide bond between C847 andC857 is
atom type. Note that C880 is only 4.5 Angstroms
Figure 5. Localization of PXDN in Embryonic and Adult Eyes
(A) Cryopreserved sagittal sections of embryonic mouse eyes at E18.5 stained with hematoxylin and eosin, anti-PXDN, or rabbit IgG
negative control. a, retina; b, lens; c, iris; d, cornea; e, lower eyelid. Note PXDN immunoreactivity, depicted as green fluorescence at
the corneal and conjunctival epithelium (f) between the corneal stroma (d) and the eyelid (e). Scale bar represents 100 mm.
(B) Sagittal cryosections of adult mouse eyes at postnatal day 60 stained with hematoxylin and eosin (scale bar represents 500 mm),
anti-PXDN, or rabbit IgG negative control (scale bar represents 100 mm). The green fluorescence corresponding to PXDN immunoreac-
tivity is abundant in the lens epithelium (g) and the corneal epithelium (f) but absent from the ciliary body (h) and iris (c). Magnified
images of (1) the lens epithelium and (2) the corneal epithelium are also shown. The basal and superficial layers of the corneal epithelium
are indicated. Scale bar represents 50 mM.C2-type immunoglobulin-like motifs,42 and a carboxy-
terminal von Willebrand factor type C domain. The latter
contains multiple cysteine residues and is thought to be
involved in forming large protein complexes with itself
and other proteins containing the VWFC domain, such
as thrombospondin and procollagen.43 It is interesting to
note that although mammalian peroxidasin usually local-
izes to the endoplasmic reticulum, it is also secreted into
the extracellular space following TGF-b-induced differenti-
ation of fibroblasts intomyofibroblasts, where it forms part
of the fibril-like network with fibronectin as well as other
extracellular matrix proteins.40 Caenorhabditis elegans per-
oxidasin (PXN-2) mutants have been shown to have aber-
rant extracellular matrix ultrastructure, in which muscles
have detached from the epidermis, supporting a role for
the normal protein in maintaining basement membrane
integrity.44 It is also worth highlighting that siRNA knock-
down of peroxidasin in cancer cells reduces the cells’
ability to attach to laminin- and fibronectin-coated wells,
further suggesting a role in cell adhesion to the extracel-
lular matrix.45
Although the mammalian PXDN transcript is expressed
in most tissues,38,40,46 the corresponding protein has only
been shown to localize to the heart and its vascularThe Americanwall.39 In light of our finding of only congenital eye defects
associated with human PXDN mutations, we investigated
the precise distribution of the normal peroxidasin protein
in mouse embryonic and adult eyes by staining serial
sections with a rabbit polyclonal antiserum against PXDN
(Figure 5). In brief, whole mouse embryos at embryonic
day 18.5 and adult eyes at postnatal day 60 were cryopre-
served according to standard procedures. The cryosections
(6 mm) were incubated with hematoxylin and eosin, anti-
PXDN (Sigma-Aldrich), or a rabbit IgG isotype negative
control (Invitrogen). Details regarding the specificity of
anti-PXDN are found at the Human Protein Atlas. Bound
primary antibodywas detectedwith Alexa Fluor 488-conju-
gated secondary antibody (Invitrogen), and the nuclei were
counterstained with DAPI (Invitrogen). Immunofluores-
cence was analyzed with an Eclipse TE2000-E inverted
confocal microscope (Nikon Instruments). At both stages
PXDN localized to the corneal epithelial layer, but for adult
eyes there was also localization to the lens epithelium.
PXDN may be involved in providing adhesive support
to these structures. However, it may also be responsible,
with other antioxidant enzymes, for metabolizing
hydrogen peroxide (H2O2), superoxide anion (O2), and
hydroxyl free radicals (OH) generated through normalJournal of Human Genetics 89, 464–473, September 9, 2011 469
Figure 6. The Generation and Metabolism of Reactive Oxygen Intermediates in the Anterior Chamber
The reactive oxygen intermediates, hydrogen peroxide (H2O2), superoxide anion (O2), and hydroxyl free radicals (OH) are highlighted
in red.Within the cornea and lens epithelial cells, O2 is generated from themitochondrial electron transport system and the activation
of surface receptors by growth factors or cytokines. H2O2 is produced either by themetabolism of O2 by superoxide dismutase or by the
molecular reaction of oxygen with ascorbate in the presence of ferric ions, and OH results from light and ultraviolet radiation as well as
from the reaction of H2O2 withmetal ions in the Fenton reaction. In terms of decomposition, H2O2 can be inactivated nonenzymatically
by reduced glutathione or enzymatically by catalase, glutathione peroxidase, or peroxidasin.metabolism in response to cytokines or exposure to light
and radiation (Figure 6).47 It is likely that peroxidasin
functions as the main extracellular antioxidant enzyme
whereas glutathione peroxidase has primarily an intracel-
lular role.
The precise mechanisms by which mutations in PXDN
lead to the abnormal lens, corneal, and glaucoma pheno-
types are unknown. It is possible that the absence of
PXDN in the cornea and lens epithelial layers causes
a buildup of reactive oxygen intermediates that indiscrim-
inately oxidize proteins and lipids, causing them to form
insoluble aggregates that lead to corneal clouding and
cataractogenesis.48–51 Although a peroxidasin knockout
mouse is not available, examination of the lens in mice
lacking glutathione peroxidase showed that they are
indeed more sensitive to oxidative stress and eventually
develop cataracts.52,53 Furthermore, a buildup of reactive
oxygen intermediates in the aqueous humor is also likely
to affect the development and differentiation of anterior
segment structures and has previously been implicated in
glaucoma pathogenesis.54 For example, enzymes induced
by oxidative stress are increased and antioxidant protective
mechanisms decreased in the aqueous humor of glaucoma
patients,55 and of all the anterior segment structures, the
trabecular meshwork is the most sensitive to oxidative
damage.56,57
In summary,wehave shownthathomozygousmutations
in PXDN cause a spectrum of ocular anterior segment
dysgenesis phenotypes, ranging from congenital cataract-470 The American Journal of Human Genetics 89, 464–473, Septembmicrocornea with mild to moderate corneal clouding to
developmental glaucoma with buphthalmos, severe opaci-
fication, and vascularization of the cornea. The observed
buphthalmos is highly suggestive of a period of severe
ocular hypertension during the perinatal period. The
common etiology of the two phenotypes was surprising,
though this may be due to genetic background or environ-
mental factors rather than a direct consequence of the
mutations observed. These findings reveal that PXDN is
important for normal development of the cornea and
lens, where it may have a role in structural support as well
as a functional role as an antioxidant protecting the lens,
trabecular meshwork, and cornea from oxidative damage.
Further work will be required to determine the precise role
of PXDN in normal ocular development and the mecha-
nism bywhich themutations cause the diverse phenotypic
consequences. Our results will also contribute toward
a more accurate classification for anterior segment condi-
tions based on genetic as well as phenotypic diagnosis.Supplemental Data
Supplemental Data include two figures and two tables and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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